JoinCare
DeSci incubation platform
Performances
Comparison
Fundraising
Follow Lists
People
About JoinCare
JoinCare is a DeSci (decentralized science) incubation platform focused on early-stage biomedical innovation. Its core business connects research teams, scientific and medical experts, ecosystem builders, and communities, providing end-to-end support from scientific discovery and evaluation to collaborative incubation. The platform builds an open incubation network and integrates an AI-assisted research system to enhance R&D efficiency and collaboration transparency.
Regarding market pain points, traditional biomedical R&D suffers from data silos, opaque funding and resource allocation, and a lack of community support for early-stage projects. JoinCare attempts to make research processes more verifiable and traceable through decentralized governance and open collaboration frameworks, while lowering the entry barrier for early-stage projects.
In the past six months (March to September 2026), JoinCare actively expanded international academic collaborations. Its CEO visited Japan's National Institute of Infectious Diseases (NIID), discussed research collaboration and infectious disease control with virology experts, and was invited to attend the 73rd Annual Meeting of the Japanese Society for Virology. These activities aim to promote data sharing and cross-border cooperation in global virology research, bringing more international scientific resources to the platform. Additionally, JoinCare continued optimizing its AI-assisted research tools and strengthened ties with global research institutions to solidify its position in the DeSci ecosystem.
JoinCare recently welcomed Natasha Sachsenmeier as Chief Technology Officer in August 2026. She brings deep expertise in Web3 and AI-driven systems, aligning with JoinCare's mission to build an open DeSci incubation network. Her appointment strengthens the team's technical leadership, particularly in advancing the CareAgents AI-assisted research system and blockchain-based infrastructure for early-stage biomedical innovation. No departures were reported.